Biotech Immunic's Q3 net loss widens

Reuters11-13

Biotech Immunic's Q3 net loss widens

Overview

Immunic reports Q3 net loss of $25.6 mln, with insufficient cash for 12 months
R&D expenses decreased by $1.4 mln in Q3 2025 compared to Q3 2024

Outlook

Company expects top-line data from phase 3 ENSURE trials by end of 2026
Company preparing further clinical testing of IMU-856, contingent on financing

Result Drivers

EMPhASIS TRIAL - Long-term phase 2 EMPhASIS data in relapsing-remitting MS showed high rates of patients free of confirmed disability worsening and favorable safety
PATENT PROTECTION - Received Notice of Allowance from USPTO for patent covering vidofludimus calcium dose strengths, potentially extending U.S. market exclusivity

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income		-$25.58 mln
Q3 Basic EPS		-$0.13
Q3 Income From Operations		-$25.99 mln
Q3 Operating Expenses		$25.99 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Immunic Inc is $4.00, about 81% above its November 12 closing price of $0.76

Press Release: ID:nPn4vXYCga

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583561159?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 19:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583561159","market":"nz","top_or_hot":-1,"title":"Biotech Immunic's Q3 net loss widens","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biotech Immunic's Q3 net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>Immunic reports Q3 net loss of $25.6 mln, with insufficient cash for 12 months</p></li><li><p>R&amp;D expenses decreased by $1.4 mln in Q3 2025 compared to Q3 2024</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects top-line data from phase 3 ENSURE trials by end of 2026</p></li><li><p>Company preparing further clinical testing of IMU-856, contingent on financing</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>EMPhASIS TRIAL - Long-term phase 2 EMPhASIS data in relapsing-remitting MS showed high rates of patients free of confirmed disability worsening and favorable safety</p></li><li><p>PATENT PROTECTION - Received Notice of Allowance from USPTO for patent covering vidofludimus calcium dose strengths, potentially extending U.S. market exclusivity</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$25.58 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.13</p></td><td></td></tr><tr><td><p>Q3 Income From Operations</p></td><td></td><td><p>-$25.99 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$25.99 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Immunic Inc is $4.00, about 81% above its November 12 closing price of $0.76</p></li></ul><p>Press Release: <span>ID:nPn4vXYCga</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech Immunic's Q3 net loss widens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech Immunic's Q3 net loss widens\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 19:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biotech Immunic's Q3 net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>Immunic reports Q3 net loss of $25.6 mln, with insufficient cash for 12 months</p></li><li><p>R&amp;D expenses decreased by $1.4 mln in Q3 2025 compared to Q3 2024</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects top-line data from phase 3 ENSURE trials by end of 2026</p></li><li><p>Company preparing further clinical testing of IMU-856, contingent on financing</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>EMPhASIS TRIAL - Long-term phase 2 EMPhASIS data in relapsing-remitting MS showed high rates of patients free of confirmed disability worsening and favorable safety</p></li><li><p>PATENT PROTECTION - Received Notice of Allowance from USPTO for patent covering vidofludimus calcium dose strengths, potentially extending U.S. market exclusivity</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$25.58 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.13</p></td><td></td></tr><tr><td><p>Q3 Income From Operations</p></td><td></td><td><p>-$25.99 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$25.99 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Immunic Inc is $4.00, about 81% above its November 12 closing price of $0.76</p></li></ul><p>Press Release: <span>ID:nPn4vXYCga</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMUX","symbol_name":"Immunic, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP0E4:1","article_id":"2583561159","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583561159","pubTimestamp":1763033905,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biotech Immunic's Q3 net loss widensOverviewImmunic reports Q3 net loss of $25.6 mln, with insufficient cash for 12 monthsR&D expenses decreased by $1.4 mln in Q3 2025 compared to Q3 2024OutlookCompan","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMUX":"Immunic, Inc.","BK4139":"生物科技"},"translate_title":"Biotech Immunic第三季度净亏损扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMUX":0.9},"content_text":"Biotech Immunic's Q3 net loss widensOverviewImmunic reports Q3 net loss of $25.6 mln, with insufficient cash for 12 monthsR&D expenses decreased by $1.4 mln in Q3 2025 compared to Q3 2024OutlookCompany expects top-line data from phase 3 ENSURE trials by end of 2026Company preparing further clinical testing of IMU-856, contingent on financingResult DriversEMPhASIS TRIAL - Long-term phase 2 EMPhASIS data in relapsing-remitting MS showed high rates of patients free of confirmed disability worsening and favorable safetyPATENT PROTECTION - Received Notice of Allowance from USPTO for patent covering vidofludimus calcium dose strengths, potentially extending U.S. market exclusivityKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income-$25.58 mlnQ3 Basic EPS-$0.13Q3 Income From Operations-$25.99 mlnQ3 Operating Expenses$25.99 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Immunic Inc is $4.00, about 81% above its November 12 closing price of $0.76Press Release: ID:nPn4vXYCgaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583561159","isCrawlerRequest":true}